RT Journal Article
SR Electronic
T1 Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with <sup>67</sup>Cu
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 829
OP 832
DO 10.2967/jnumed.120.251579
VO 62
IS 6
A1 Lachlan E. McInnes
A1 Carleen Cullinane
A1 Peter D. Roselt
A1 Susan Jackson
A1 Benjamin J. Blyth
A1 Ellen M. van Dam
A1 Nicholas A. Zia
A1 Matthew J. Harris
A1 Rodney J. Hicks
A1 Paul S. Donnelly
YR 2021
UL http://jnm.snmjournals.org/content/62/6/829.abstract
AB Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&amp;T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.